Price Alert

Neurocrine Biosciences In... (NBIX)

NASDAQ: NBIX · Real-Time Price · USD

132.98

1.67 (1.27%)

At close: Aug 15, 2025, 1:19 PM

Neurocrine Biosciences Statistics

Share Statistics

Neurocrine Biosciences has 99.18M shares outstanding. The number of shares has increased by -1.99% in one year.

Shares Outstanding	99.18M
Shares Change (YoY)	-1.99%
Shares Change (QoQ)	-0.74%
Owned by Institutions (%)	94.43%
Shares Floating	95.68M
Failed to Deliver (FTD) Shares	2,535
FTD / Avg. Volume	0.25%

Short Selling Information

The latest short interest is 3.23M, so 3.27% of the outstanding shares have been sold short.

Short Interest	3.23M
Short % of Shares Out	3.27%
Short % of Float	4.36%
Short Ratio (days to cover)	4.06

Valuation Ratios

The PE ratio is 40.15 and the forward PE ratio is 19.37. Neurocrine Biosciences's PEG ratio is 1.22.

PE Ratio	40.15
Forward PE	19.37
PS Ratio	5.82
Forward PS	3.8
PB Ratio	5.29
P/FCF Ratio	24.6
PEG Ratio	1.22

Financial Ratio History

Enterprise Valuation

Neurocrine Biosciences has an Enterprise Value (EV) of 13.93B.

EV / Sales	5.91
EV / EBITDA	21.77
EV / EBIT	23.39
EV / FCF	24.99

Financial Position

The company has a current ratio of 3.4, with a Debt / Equity ratio of 0.18.

Current Ratio	3.4
Quick Ratio	3.28
Debt / Equity	0.18
Debt / EBITDA	0.71
Debt / FCF	0.82
Interest Coverage	4.51

Financial Efficiency

Return on Equity is 13.18% and Return on Invested Capital is 12.48%.

Return on Equity	13.18%
Return on Assets	9.18%
Return on Invested Capital	12.48%
Revenue Per Employee	$1.31M
Profits Per Employee	$189.61K
Employee Count	1,800
Asset Turnover	0.63
Inventory Turnover	0.59

Taxes

Income Tax	144.7M
Effective Tax Rate	29.77%

Stock Price Statistics

The stock price has increased by -15.82% in the last 52 weeks. The beta is 0.25, so Neurocrine Biosciences's price volatility has been higher than the market average.

Beta	0.25
52-Week Price Change	-15.82%
50-Day Moving Average	128.57
200-Day Moving Average	123.46
Relative Strength Index (RSI)	38.98
Average Volume (20 Days)	996,020

Income Statement

In the last 12 months, Neurocrine Biosciences had revenue of 2.36B and earned 341.3M in profits. Earnings per share was 3.4.

Revenue	2.36B
Gross Profit	2.32B
Operating Income	570.5M
Net Income	341.3M
EBITDA	639.7M
EBIT	612.6M
Earnings Per Share (EPS)	3.4

Full Income Statement

Balance Sheet

The company has 233M in cash and 455.1M in debt, giving a net cash position of -222.1M.

Cash & Cash Equivalents	233M
Total Debt	455.1M
Net Cash	-222.1M
Retained Earnings	29.2M
Total Assets	3.89B
Working Capital	1.2B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 595.4M and capital expenditures -38.2M, giving a free cash flow of 557.2M.

Operating Cash Flow	595.4M
Capital Expenditures	-38.2M
Free Cash Flow	557.2M
FCF Per Share	5.55

Full Cash Flow Statement

Margins

Gross margin is 98.56%, with operating and profit margins of 24.22% and 14.49%.

Gross Margin	98.56%
Operating Margin	24.22%
Pretax Margin	20.63%
Profit Margin	14.49%
EBITDA Margin	27.16%
EBIT Margin	24.22%
FCF Margin	23.66%

Dividends & Yields

NBIX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	2.49%
FCF Yield	4.07%

Dividend Details

Analyst Forecast

The average price target for NBIX is $165, which is 33.1% higher than the current price. The consensus rating is "Buy".

Price Target	$165
Price Target Difference	33.1%
Analyst Consensus	Buy
Analyst Count	20

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	$17
Lynch Upside	-86.29%
Graham Number	44.42
Graham Upside	-64.17%

Scores

Altman Z-Score	7.72
Piotroski F-Score	7